The Company has been informed that on 22 July 2013 certain Directors of the Company purchased ordinary shares in the Company as follows:
| Director |
No. of Shares purchased |
Price at which shares purchased |
No. of shares held pursuant to transaction (% of ISC following transaction) |
| David Evans |
30,000 |
31.8 pence |
5,130,000
(2.6%)
|
| Kate Cornish-Bowden |
45,000 |
32.0 pence |
45,000
(0.02%)
|
For Further Information:
Scancell Holdings Plc
Dr Richard Goodfellow, Joint CEO + 44 (0) 74 2323 0 497
Professor Lindy Durrant, Joint CEO
Cenkos Securities
Camilla Hume +44 (0) 20 7397 8900
Stephen Keys
FTI Consulting
Simon Conway +44 (0) 20 7831 3113
Mo Noonan
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.